Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 3832K) PDF+supp data (7769K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oresic, M. Articles by Simell, O. Search for Related Content PubMed PubMed Citation Articles by Oresic, M. Articles by Simell, O. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Diabetes Type 1 Metabolic Disorders Related Collections Related Article Social Bookmarking                            What's this?

Matej Orei¹, Satu Simell², Marko Sysi-Aho¹, Kirsti Näntö-Salonen², Tuulikki Seppänen-Laakso¹, Vilhelmiina Parikka², Mikko Katajamaa¹, Anne Hekkala⁴, Ismo Mattila¹, Päivi Keskinen⁵, Laxman Yetukuri¹, Arja Reinikainen⁶, Jyrki Lähde⁵, Tapani Suortti¹, Jari Hakalax², Tuula Simell², Heikki Hyöty^7,8, Riitta Veijola⁴, Jorma Ilonen^3,9, Riitta Lahesmaa⁶, Mikael Knip^5,10, and Olli Simell²

¹ VTT Technical Research Centre of Finland, Espoo FI-02044, Finland
² Department of Pediatrics and ³ Immunogenetics Laboratory, University of Turku, Turku FI-20520, Finland
⁴ Department of Pediatrics, University of Oulu, Oulu FI-90014, Finland
⁵ Department of Pediatrics, Tampere University Hospital, Tampere FI-33521, Finland
⁶ Turku Centre for Biotechnology, Turku FI-20521, Finland
⁷ Department of Virology, University of Tampere, Tampere FI-33520, Finland
⁸ Centre for Laboratory Medicine, University Hospital of Tampere, Tampere FI-33520, Finland
⁹ Department of Clinical Microbiology, University of Kuopio, FI-70211 Kuopio, Finland
¹⁰ Hospital for Children and Adolescents, University of Helsinki, Helsinki FI-00014, Finland

CORRESPONDENCE Matej Orei: matej.oresic{at}vtt.fi OR Olli Simell: olli.simell{at}utu.fi

The risk determinants of type 1 diabetes, initiators of autoimmune response, mechanisms regulating progress toward β cell failure, and factors determining time of presentation of clinical diabetes are poorly understood. We investigated changes in the serum metabolome prospectively in children who later progressed to type 1 diabetes. Serum metabolite profiles were compared between sample series drawn from 56 children who progressed to type 1 diabetes and 73 controls who remained nondiabetic and permanently autoantibody negative. Individuals who developed diabetes had reduced serum levels of succinic acid and phosphatidylcholine (PC) at birth, reduced levels of triglycerides and antioxidant ether phospholipids throughout the follow up, and increased levels of proinflammatory lysoPCs several months before seroconversion to autoantibody positivity. The lipid changes were not attributable to HLA-associated genetic risk. The appearance of insulin and glutamic acid decarboxylase autoantibodies was preceded by diminished ketoleucine and elevated glutamic acid. The metabolic profile was partially normalized after the seroconversion. Autoimmunity may thus be a relatively late response to the early metabolic disturbances. Recognition of these preautoimmune alterations may aid in studies of disease pathogenesis and may open a time window for novel type 1 diabetes prevention strategies.

Abbreviations used: BCAA, branched chain amino acids; DIPP, Type 1 Diabetes prediction and prevention study; GABA, -aminobutyric acid; GADA, glutamic acid decarboxylase antibody; GCxGC-TOF/MS, two-dimensional gas chromatography coupled to time-of-flight mass spectrometry; IAA, insulin autoantibody; ICA, islet cell autoantibody; PC, phosphatidylcholine; STRIP, Special Turku Coronary Risk Factor Intervention Project for Children.

S. Simell, M. Sysi-Aho, K. Näntö-Salonen, T. Seppänen-Laakso, V. Parikka, and M. Katajamaa contributed equally to this paper.

© 2008 Orei et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

Causes of early-onset type 1 diabetes: toward data-driven environmental approaches

Pierre Bougnères and Alain-Jacques Valleron
J. Exp. Med. 2008 205: 2953-2957. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Bain, J. R., Stevens, R. D., Wenner, B. R., Ilkayeva, O., Muoio, D. M., Newgard, C. B. (2009). Metabolomics Applied to Diabetes Research: Moving From Information to Knowledge. Diabetes 58: 2429-2443 [Full Text]  
• Bougneres, P., Valleron, A.-J. (2008). Causes of early-onset type 1 diabetes: toward data-driven environmental approaches. JEM 205: 2953-2957 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS